Reassessing the use of vasodilators in heart failure

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 9, 2012, Pages 1141-1151

  Cole, Robert T ^a   Gheorghiade, Mihai ^b   Georgiopoulou, Vasiliki V ^a   Gupta, Divya ^a   Marti, Catherine N ^a   Kalogeropoulos, Andreas P ^a   Butler, Javed ^a  

^a EMORY UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

heart failure; hemodynamics; hydralazine; isosorbide dinitrate; nesiritide; tailored therapy; vasodilators

Indexed keywords

AMLODIPINE; BOSENTAN; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENOXIMONE; FELODIPINE; FLOSEQUINAN; GLYCERYL TRINITRATE; HYDRALAZINE; MILRINONE; MINOXIDIL; NESIRITIDE; NIFEDIPINE; NITRATE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V INHIBITOR; PRAZOSIN; PROSTACYCLIN; SILDENAFIL; TADALAFIL; TEZOSENTAN; VASODILATOR AGENT; VERAPAMIL;

DISEASE ASSOCIATION; DRUG DOSE TITRATION; HEART FAILURE; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LUNG WEDGE PRESSURE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SYSTEMIC VASCULAR RESISTANCE; TREATMENT OUTCOME; UNITED STATES; VASODILATATION;

ANIMALS; EVIDENCE-BASED MEDICINE; HEART FAILURE; HEMODYNAMICS; HUMANS; INDIVIDUALIZED MEDICINE; VASODILATOR AGENTS;

EID: 84867958087     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.108     Document Type: Review

References (80)

1. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics - 2011 update: a report from the american heart association. Circulation 1c23, e18-e209 (2011)
2. Rose EA, Gelijns AC, Moskowitz AJ et al.; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 345(20), 1435-1443 (2001)
3. Imperial ES, Levy MN, Zieske H. Outflow resistance as an independent determinant of cardiac performance. Circ. Res. 9, 1148-1155 (1961)
4. Sonnenblick EH, Downing SE. Afterload as a primary determinat of ventricular performance. Am. J. Physiol. 204, 604-610 (1963)
5. Franciosa JA, Cohn JN. Effects of minoxidil on hemodynamics in patients with congestive heart failure. Circulation 63(3), 652-657 (1981) (Pubitemid 11139876)
6. Franciosa JA, Limas CJ, Guiha NH, Rodriguera E, Cohn JN. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet 1(7752), 650-654 (1972)
7. Franciosa JA, Mikulic E, Cohn JN, Jose E, Fabie A. Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure. Circulation 50(5), 1020-1024 (1974)
8. Franciosa JA, Pierpont G, Cohn JN. Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients. Ann. Intern. Med. 86(4), 388-393 (1977) (Pubitemid 8078945)
9. Guiha NH, Cohn JN, Mikulic E, Franciosa JA, Limas CJ. Treatment of refractory heart failure with infusion of nitroprusside. N. Engl. J. Med. 291(12), 587-592 (1974)
10. Miller RR, Awan NA, Maxwell KS, Mason DT. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N. Engl. J. Med. 297(6), 303-307 (1977) (Pubitemid 8161784)
11. Schreiber R, Maier PT, Gunnar RM, Loeb HS. Hemodynamic improvement following a single dose of oral phentolamine. Administration in patients with chronic low output cardiac failure. Chest 76(5), 571-575 (1979) (Pubitemid 10131004)
12. Massie B, Chatterjee K, Werner J, Greenberg B, Hart R, Parmley WW. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am. J. Cardiol. 40(5), 794-801 (1977) (Pubitemid 8225612)
13. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 314(24), 1547-1552 (1986) (Pubitemid 16114684)
14. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine- isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325(5), 303-310 (1991)
15. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilatorheart failure trials. Vasodilator-Heart Failure Trial Study Group. J. Card. Fail. 5(3), 178-187 (1999) (Pubitemid 29449255)
16. Taylor AL, Ziesche S, Yancy C et al.; African American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351(20), 2049-2057 (2004)
17. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation 99(1), 90-95 (1999) (Pubitemid 29035962)
18. Cole RT, Kalogeropoulos AP, Georgiopoulou VV et al. Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation 123(21), 2414-2422 (2011)
19. Stein CM, Lang CC, Nelson R, Brown M, Wood AJ. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin. Pharmacol. Ther. 62(4), 436-443 (1997) (Pubitemid 27475228)
20. Vita JA. Nitric oxide and vascular reactivity in African American patients with hypertension. J. Card. Fail. 9(Suppl. 5), S199-S204; discussion S205 (2003) (Pubitemid 41096360)
21. Daiber A, Oelze M, Coldewey M et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem. Biophys. Res. Commun. 338(4), 1865-1874 (2005) (Pubitemid 41643103)
22. Münzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 123(19), 2132-2144 (2011)
23. Münzel T, Kurz S, Rajagopalan S et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J. Clin. Invest. 98(6), 1465-1470 (1996) (Pubitemid 26322073)
24. Hare JM. Nitroso-redox balance in the cardiovascular system. N. Engl. J. Med. 351(20), 2112-2114 (2004) (Pubitemid 39482505)
25. The consensus trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (consensus) N. Engl. J. Med. 316, 1429-1435 (1987)
26. The solvd investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991)
27. The acute infarction ramipril efficacy (aire) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342, 821-828 (1993)
28. Braunwald E. ACE inhibitors - a cornerstone of the treatment of heart failure. N. Engl. J. Med. 325(5), 351-353 (1991)
29. Køber L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensinconverting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. 333(25), 1670-1676 (1995)
30. Rydén L, Armstrong PW, Cleland JG et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur. Heart J. 21(23), 1967-1978 (2000)
31. Stevenson LW, Tillisch JH. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. Circulation 74(6), 1303-1308 (1986) (Pubitemid 17189249)
32. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 51(5), 831-836 (1983) (Pubitemid 13141977)
33. Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am. J. Cardiol. 54(1), 147-152 (1984) (Pubitemid 14085366)
34. Johnson W, Omland T, Hall C et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J. Am. Coll. Cardiol. 39(10), 1623-1629 (2002) (Pubitemid 34494285)
35. Stevenson LW, Sietsema K, Tillisch JH et al. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. Circulation 81(1), 78-85 (1990) (Pubitemid 20031770)
36. Stevenson LW, Steimle AE, Fonarow G et al. Improvement in exercise capacity of candidates awaiting heart transplantation. J. Am. Coll. Cardiol. 25(1), 163-170 (1995)
37. Hamilton MA, Stevenson LW, Child JS, Moriguchi JD, Walden J, Woo M. Sustained reduction in valvular regurgitation and atrial volumes with tailored vasodilator therapy in advanced congestive heart failure secondary to dilated (ischemic or idiopathic) cardiomyopathy. Am. J. Cardiol. 67(4), 259-263 (1991)
38. Rosario LB, Stevenson LW, Solomon SD, Lee RT, Reimold SC. The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J. Am. Coll. Cardiol. 32(7), 1819-1824 (1998) (Pubitemid 29010440)
39. Stevenson LW, Dracup KA, Tillisch JH. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am. J. Cardiol. 63(7), 461-464 (1989) (Pubitemid 19065323)
40. Steimle AE, Stevenson LW, Chelimsky- Fallick C et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 96(4), 1165-1172 (1997) (Pubitemid 27344219)
41. Stevenson LW, Tillisch JH, Hamilton M et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am. J. Cardiol. 66(19), 1348-1354 (1990)
42. Massie BM, Kramer BL, Topic N. Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation 69(6), 1135-1141 (1984) (Pubitemid 14108793)
43. Walsh WF, Greenberg BH. Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 64(3), 499-505 (1981) (Pubitemid 11061618)
44. Franciosa JA, Goldsmith SR, Cohn JN. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am. J. Med. 69(4), 559-566 (1980) (Pubitemid 10018711)
45. Levine TB, Franciosa JA, Cohn JN. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation 62(1), 35-41 (1980) (Pubitemid 10083094)
46. Massie B, Ports T, Chatterjee K et al. Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation 63(2), 269-278 (1981) (Pubitemid 11168742)
47. Massie BM, Kramer B, Haughom F. Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance. Circulation 64(6), 1218-1226 (1981) (Pubitemid 12236152)
48. Packer M, Meller J, Gorlin R, Herman MV. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation 59(3), 531-539 (1979) (Pubitemid 9129666)
49. Binanay C, Califf RM, Hasselblad V et al.; ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294(13), 1625-1633 (2005)
50. Allhat Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (allhat) JAMA 283, 1967-1975 (2000)
51. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287, 1531-1540 (2002)
52. Mentzer RM Jr, Oz MC, Sladen RN et al.; NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J. Am. Coll. Cardiol. 49(6), 716-726 (2007) (Pubitemid 46205038)
53. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111(12), 1487-1491 (2005) (Pubitemid 40470642)
54. Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA 296(12), 1465-1466 (2006) (Pubitemid 44465509)
55. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am. Heart J. 152(6), 1084-1090 (2006) (Pubitemid 44854791)
56. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293(15), 1900-1905 (2005) (Pubitemid 40548187)
57. O'Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365(1), 32-43 (2011)
58. Califf RM, Adams KF, McKenna WJ et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST) Am. Heart J. 134(1), 44-54 (1997) (Pubitemid 27329022)
59. Moe GW, Rouleau JL, Charbonneau L et al. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. Am. Heart J. 139(4), 587-595 (2000) (Pubitemid 30207783)
60. Packer M, O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N. Engl. J. Med. 335(15), 1107-1114 (1996) (Pubitemid 26330964)
61. Cohn JN, Ziesche S, Smith R et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator- Heart Failure Trial (V-HeFT) Study Group. Circulation 96(3), 856-863 (1997) (Pubitemid 27329620)
62. McMurray JJ, Teerlink JR, Cotter G et al.; VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298(17), 2009-2019 (2007) (Pubitemid 350074798)
63. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J. Am. Coll. Cardiol. 59(5), 442-451 (2012)
64. Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287(12), 1541-1547 (2002) (Pubitemid 34269999)
65. Felker GM, Benza RL, Chandler AB et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J. Am. Coll. Cardiol. 41(6), 997-1003 (2003) (Pubitemid 36315544)
66. Izzo JL Jr, Licht MR, Smith RJ, Larrabee PS, Radke KJ, Kallay MC. Chronic effects of direct vasodilation (pinacidil), α-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. Am. J. Cardiol. 60(4), 303-308 (1987) (Pubitemid 17133059)
67. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N. Engl. J. Med. 327(10), 678-684 (1992)
68. Markham RV Jr, Corbett JR, Gilmore A, Pettinger WA, Firth BG. Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebocontrolled study. Am. J. Cardiol. 51(8), 1346-1352 (1983) (Pubitemid 13133077)
69. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 82(6), 1954-1961 (1990)
70. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II) Am. J. Cardiol. 66, 779-785 (1990)
71. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 83(1), 52-60 (1991)
72. Packer M. Results from late-breaking clinical trials sessions: Praise-2. J. Am. Coll. Cardiol. 36, 255-261 (2000)
73. Packer M, McMurray J, Massie BM et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J. Card. Fail. 11(1), 12-20 (2005) (Pubitemid 40215308)
74. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for nonselective endothelin antagonism in heart failure? Int. J. Cardiol. 85(2-3), 195-197 (2002) (Pubitemid 35245980)
75. Coletta AP, Cleland JG. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur. J. Heart Fail. 3(6), 747-750 (2001) (Pubitemid 33123176)
76. O'Connor CM, Gattis WA, Adams KF Jr et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4) J. Am. Coll. Cardiol. 41(9), 1452-1457 (2003) (Pubitemid 36543358)
77. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325(21), 1468-1475 (1991)
78. Uretsky BF, Jessup M, Konstam MA et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 82(3), 774-780 (1990) (Pubitemid 20316728)
79. Packer M, Rouleau JL, Swedberg K, Pitt B, Fisher L, Klepper M. Effect of flosequinan on survival in chronic heart failure: preliminary results of the profile study. Circulation 88(Suppl. 1), 301 (1993)
80. Franciosa JA, Jordan RA, Wilen MM, Leddy CL. Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. Circulation 70(1), 63-68 (1984) (Pubitemid 14084067)